Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
Frontiers in Pharmacology · 06.06.2023 · 14
DOI: 10.3389/fphar.2023.1142680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.06.2023. Verfasst von Elizabeth A Cairns und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Evidence is accumulating that components of the Cannabis sativa plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors.
Methods
The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general cannabinoid content of products. The conditions treated were categorized according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, text revision (DSM-5-TR). Trends in prescribing for conditions over time were analyzed via polynomial regression, and relationships between categorical variables determined via correspondence analyses.
Results
Approximately 300,000 SAS-B approvals to prescribe MC had been issued in the time period under investigation. This included approvals for 38 different DSM-5-TR defined psychiatric conditions (33.9% of total approvals). The majority of approvals were for anxiety disorders (66.7% of psychiatry-related prescribing), sleep-wake disorders (18.2%), trauma- and stressor-related disorders (5.8%), and neurodevelopmental disorders (4.4%). Oil products were most prescribed (53.0%), followed by flower (31.2%) and other inhaled products (12.4%). CBD-dominant products comprised around 20% of total prescribing and were particularly prevalent in the treatment of autism spectrum disorder. The largest proportion of approvals was for patients aged 25–39 years (46.2% of approvals). Recent dramatic increases in prescribing for attention deficit hyperactivity disorder were identified.
Conclusion
A significant proportion of MC prescribing in Australia is for psychiatry-related indications. This prescribing often appears somewhat “experimental”, given it involves conditions (e.g., ADHD, depression) for which definitive clinical evidence of MC efficacy is lacking. The high prevalence of THC-containing products being prescribed is of possible concern given the psychiatric problems associated with this drug. Evidence-based clinical guidance around the use of MC products in psychiatry is lacking and would clearly be of benefit to prescribers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
- Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.
- Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia.
- Faculty of Science, School of Psychology, The University of Sydney, Sydney, NSW, Australia.
- Centre for Healthy Brain Ageing (CHeBA), Discipline of Psychiatry and Mental Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia.
- Neuropsychiatric Institute, The Prince of Wales Hospital, Randwick, NSW, Australia.
Zitieren
APA
Cairns, E. A., Benson, M. J., Bedoya-Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R., Sachdev, P. S., & McGregor, I. S. (2023). Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1142680
Vancouver
Cairns EA, Benson MJ, Bedoya-Pérez MA, Macphail SL, Mohan A, Cohen R, et al. Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1142680
BibTeX
@article{Cairns2023,
author = {Cairns, Elizabeth A and Benson, Melissa J and Bedoya-Pérez, Miguel A and Macphail, Sara L and Mohan, Adith and Cohen, Rhys and Sachdev, Perminder S and McGregor, Iain S},
title = {Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1142680}
}
EUVIMED